Scarica l'app Stockscreener
4.22
7.25%
-0.33
Dopo l'orario di chiusura:
4.27
0.05
+1.18%
Precedente Chiudi:
$4.55
Aprire:
$4.62
Volume 24 ore:
1.50M
Relative Volume:
1.17
Capitalizzazione di mercato:
$117.55M
Reddito:
$675.00K
Utile/perdita netta:
$-39.95M
Rapporto P/E:
-2.0521
EPS:
-2.0564
Flusso di cassa netto:
$-28.67M
1 W Prestazione:
-10.12%
1M Prestazione:
-18.69%
6M Prestazione:
-39.11%
1 anno Prestazione:
-8.66%
Intervallo 1D:
$4.09
$4.62
Intervallo di 1 settimana:
$4.09
$4.81
Portata 52W:
$3.93
$8.74
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Nome
Unicycive Therapeutics Inc
Settore
Industria
Telefono
650-384-0642
Indirizzo
1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW
Compare UNCY vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
4.22 | 130.78M | 675.00K | -39.95M | -28.67M | -2.0564 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-21 | Iniziato | Guggenheim | Buy |
| 2024-04-04 | Iniziato | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Borsa (UNCY) Ultime notizie
DEADLINE ALERT for HYLN, HIMS, UNCY, BIDU: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Unicycive - GlobeNewswire
Unicycive Therapeutics, Inc. Appoints Meredith Manning to its Board of Directors, Each of the Audit, Compensation, and Nominating and Corporate Governance Committees, and Chairperson of the Nominating and Corporate Governance Committee - marketscreener.com
UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action LawsuitInvestors With Losses May Contact SueWallSt - PR Newswire
Unicycive Therapeutics Appoints Meredith Manning To Board Of Directors - TradingView
Unicycive appoints Meredith Manning to board of directors By Investing.com - Investing.com UK
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors - Carroll County Mirror-Democrat
Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire
Lost Money on Unicycive Therapeutics, Inc. (UNCY)? Contact Levi & Korsinsky Before November 2, 2026 to Join Class Action - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 2, 2026 in Unicycive Therapeutics, Inc. LawsuitUNCY - PR Newswire
Unicycive's drug was rejected twice by regulators, but CEO hopes third time is the charm - The Business Journals
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate - floridatoday.com
Robbins LLP Urges UNCY Stockholders with Significant Losses to Contact the Firm for Information About the Unicycive Therapeutics, Inc. Class Action - PR Newswire
UNCY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Deadline Alert: Unicycive Therapeutics, Inc. (UNCY) - GlobeNewswire
H.C. Wainwright Maintains Unicycive Therapeutics(UNCY.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
HC Wainwright & Co. maintains Buy rating on Unicycive Therapeutics, $13 price target - TradingView
Unicycive Therapeutics resubmits oxylanthanum carbonate NDA to FDA - Mugglehead Investment Magazine
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Unicycive Therapeutics faces securities class action lawsuit over public statements - Investing.com Nigeria
Unicycive Faces New Securities Class Action Over NDA Disclosures - TipRanks
UNCY SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Form 8K Unicycive Therapeutics Inc For: 28 September By Investing.com - Investing.com Canada
[8-K] Unicycive Therapeutics, Inc. Reports Material Event - Stock Titan
Unicycive Therapeutics stock sits 47.03 percent below its 52-week high - AD HOC NEWS
Kaplan Fox Deadline Alert: Unicycive Therapeutics, Inc. (NASDAQ - The National Law Review
UNCY Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
Faruqi & Faruqi, LLP Urges Unicycive Therapeutics, Inc. (UNCY) In - The National Law Review
Faruqi & Faruqi, LLP Urges Unicycive Therapeutics, Inc. (UNCY) Investors to Seek Counsel Before the November 2, 2026 Lead Plaintiff Deadline in the Securities Class Action - TMX Newsfile
Shareholders of Unicycive Therapeutics, Inc. (UNCY): Protect Your Rights Before November 2, 2026 – Contact Levi & Korsinsky - ACCESS Newswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionUNCY - TMX Newsfile
UNCY Should I Buy - Intellectia AI
Lost Money on Unicycive Therapeutics, Inc. (UNCY)? Join Class Action Before November 2, 2026Contact Levi & Korsinsky - ACCESS Newswire
UNCY Stockholders Have Rights – If You Lost Money Investing - GlobeNewswire
UNCY INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Unicycive Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
UNCY Stock Clocks Worst Day In A Year — Analysts Keep Buy Ratings Despite ‘5-12 Month Delay’ In Drug Approval - Stocktwits
UNCY Stock Crashed 45% Today – Why Did FDA Reject Its Kidney Disease NDA For A Second Time? - Stocktwits
Levi & Korsinsky Urges Unicycive Therapeutics, Inc. (UNCY) Shareholders to Act Before Lead Plaintiff Deadline November 2, 2026 - ACCESS Newswire
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of November 2, 2026 Deadline - ACCESS Newswire
Lost Money on Unicycive Therapeutics, Inc. (UNCY)? Urged to Join Class Action Before November 2, 2026Contact Levi & Korsinsky - ACCESS Newswire
Class Action Filed Against Unicycive Therapeutics, Inc. (UNCY) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Deadline on November 2, 2026 - The Globe and Mail
UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class ActionContact SueWallSt - PR Newswire
Securities Class Action Lawsuit Filed Against Unicycive Therapeutics, Inc. (UNCY)Levi & Korsinsky Represents Shareholders - ACCESS Newswire
UNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action NoticeContact Levi & Korsinsky - AOL.ca
Did You Lose Money on Unicycive Therapeutics, Inc. (UNCY)? Levi & Korsinsky Urges Investors to Act Before November 2, 2026 - ACCESS Newswire
UNCY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicyci - The National Law Review
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Unicycive - GlobeNewswire
Kaplan Fox Encourages Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Investors to Contact the Firm Before the Lead Plaintiff Deadline on November 2, 2026 - NewMediaWire
Unicycive Therapeutics Inc Azioni (UNCY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):